Prelude Therapeutics (PRLD) 2025 Conference Transcript

Prelude Therapeutics (PRLD) 2025 Conference May 07, 2025 11:00 AM ET Speaker0 I've been working on it for a awhile but now we have two molecules, one an IV and one an oral agent, both in the clinic that are targeting a very unique pathway called SMARK pathway, desired SMARK2 degraders, and there is a high unmet need in patients who have this mutation since SMARK4, a related family member that results in pretty aggressive cancers across multiple cancer types. So we've made a lot of progress. We demonstrated ...